MOTS-C dosage frequency is not standardized in humans. Research protocols typically use 5–10 mg per week split into 2–3 injections. Learn more.
MOTS-C dosage frequency is not established in human medicine because MOTS-C is not an FDA-approved drug. In animal studies and community research protocols, the peptide is most often injected 2 to 3 times per week, with total weekly doses around 5 to 10 mg. No human trial has confirmed a safe or effective injection schedule.
What MOTS-C Is and Why Frequency Matters
MOTS-C is a mitochondrial-derived peptide that helps regulate metabolic homeostasis, insulin sensitivity, and the body's response to exercise. It is encoded in mitochondrial DNA and acts on skeletal muscle and adipose tissue. In rodent studies, MOTS-C injections improve glucose tolerance and physical performance, but these results do not prove the same effects in humans.
The peptide has a short half-life in circulation, which is why many protocols split a weekly dose into multiple injections instead of one large dose. A single injection may lower blood glucose for hours, not days, in animal models.
MOTS-C is not approved by the FDA for human use, and no official dosing frequency exists.
Common MOTS-C Dosage Frequency Protocols
Because human data are lacking, most available information comes from rodent research and online self-experimentation logs. Common frequencies include:
- Twice per week: 2.5–5 mg per injection, for a weekly total of 5–10 mg.
- Three times per week: 2–3.3 mg per injection, for a weekly total of 6–10 mg. This is the most frequently reported schedule.
- Every other day: 1–2 mg per injection, for a weekly total of 4–8 mg.
- Five days on, two days off: 1–2 mg per injection, used by some to mimic pulsatile release.
Subcutaneous injection is the standard route in these protocols, and some users rotate injection sites to reduce irritation. There is no consensus on whether morning or evening injections are better.
A typical mots-c dosage per week in these protocols is 10 mg, split into two or three subcutaneous injections. Many researchers follow a mots-c peptide dosage protocol that runs for 4 to 8 weeks, followed by a break.
| Frequency | Total weekly dose | Typical per-injection amount | Notes |
|---|---|---|---|
| 2x per week | 5–10 mg | 2.5–5 mg | Convenient; fewer injections |
| 3x per week | 6–10 mg | 2–3.3 mg | Most common in community logs |
| Every other day | 4–8 mg | 1–2 mg | May better match short half-life |
| Daily | 3.5–7 mg | 0.5–1 mg | Rare; higher injection burden |
MOTS-C Dosage Chart: Weekly Ranges and Cycle Length
A mots-c dosage chart can help organize a research plan, but it cannot replace medical supervision. Cycle length in most protocols is 4 to 12 weeks. Some users report 8 weeks on and 4 weeks off.
The chart below reflects ranges reported in online peptide communities, not clinical guidelines. Higher weekly doses are not necessarily more effective, and rodent doses do not translate directly to humans.
| Weekly dose | Frequency | Per-injection amount | Typical cycle |
|---|---|---|---|
| 5 mg | 2x per week | 2.5 mg | 4–8 weeks |
| 10 mg | 2x per week | 5 mg | 4–8 weeks |
| 10 mg | 3x per week | ~3.3 mg | 4–8 weeks |
| 15 mg | 3x per week | 5 mg | 4–6 weeks (less common) |
MOTS-C Dosage for Weight Loss and for Women
The search phrase mots-c dosage for weight loss is common, but no human trial has shown that MOTS-C causes weight loss. Animal studies suggest MOTS-C may improve insulin sensitivity and fat oxidation, yet these are not weight-loss cures.
There is no separate dosage for women in the scientific literature. Women in community protocols generally use the same weekly ranges as men, though a lower body weight may justify starting at the lower end.
Women who are pregnant, breastfeeding, or have a history of hormone-sensitive conditions should avoid research peptides entirely. Some researchers compare aod-9604 mots-c tesamorelin dosage regimens when studying metabolic peptides, but each compound has its own distinct research profile.
Safety, Side Effects, and Legal Status
MOTS-C is sold as a research chemical, not as a prescription drug. The FDA has not approved it for any human condition, and selling it for human consumption is illegal in the United States.
Reported side effects from anecdotal use include injection site reactions, fatigue, and headache. No controlled human safety data exist. Injecting any research peptide carries risks of infection, allergic reaction, and unknown long-term effects.
Quality control is another major concern. Many online vendors sell peptides with unknown purity or contaminants. Legal status varies by country, but in the US, MOTS-C is not approved for human use.
Consult a licensed healthcare professional before using MOTS-C or any research peptide.
Frequently Asked Questions
What is the typical MOTS-C dosage frequency?
Most research protocols use 2 to 3 subcutaneous injections per week, with total weekly amounts of 5 to 10 mg. No human trial has established a safe or effective frequency, so these numbers come from animal studies and community reports.
How many mg of MOTS-C per week do people use?
Common weekly totals in online protocols are 5 mg to 10 mg. Some users report up to 15 mg per week, but higher doses are not supported by human safety data. Always consult a healthcare professional before using any research peptide.
Is MOTS-C dosage different for women?
No official sex-specific dosage exists. Women in community protocols generally follow the same weekly ranges as men, though lower body weight may lead to lower absolute doses. Pregnant or breastfeeding women should avoid MOTS-C entirely.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.